379 related articles for article (PubMed ID: 29895626)
1. Evaluating measurable residual disease in acute myeloid leukemia.
Ravandi F; Walter RB; Freeman SD
Blood Adv; 2018 Jun; 2(11):1356-1366. PubMed ID: 29895626
[TBL] [Abstract][Full Text] [Related]
2. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
3. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ; Heuser M; Freeman S; Béné MC; Buccisano F; Cloos J; Grimwade D; Haferlach T; Hills RK; Hourigan CS; Jorgensen JL; Kern W; Lacombe F; Maurillo L; Preudhomme C; van der Reijden BA; Thiede C; Venditti A; Vyas P; Wood BL; Walter RB; Döhner K; Roboz GJ; Ossenkoppele GJ
Blood; 2018 Mar; 131(12):1275-1291. PubMed ID: 29330221
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
[TBL] [Abstract][Full Text] [Related]
5. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
6. Is it time to routinely incorporate MRD into practice?
Ravandi F
Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
[TBL] [Abstract][Full Text] [Related]
7. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
8. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
Paterno G; Del Principe MI; Venditti A
Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
[TBL] [Abstract][Full Text] [Related]
9. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
12. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
13. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
15. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
16. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
Walter RB; Ofran Y; Wierzbowska A; Ravandi F; Hourigan CS; Ngai LL; Venditti A; Buccisano F; Ossenkoppele GJ; Roboz GJ
Leukemia; 2021 Jun; 35(6):1529-1538. PubMed ID: 33758317
[TBL] [Abstract][Full Text] [Related]
18. Impact of detectable measurable residual disease on umbilical cord blood transplantation.
Baron F; Labopin M; Ruggeri A; Sierra J; Robinson S; Labussière-Wallet H; Potter M; Ribera JM; Deconinck E; Rambaldi A; Rohrlich PS; de Revel T; Gluckman E; Nagler A; Mohty M
Am J Hematol; 2020 Sep; 95(9):1057-1065. PubMed ID: 32449964
[TBL] [Abstract][Full Text] [Related]
19. Can we incorporate MRD assessment into clinical practice in AML?
Ossenkoppele G; Schuurhuis GJ; van de Loosdrecht A; Cloos J
Best Pract Res Clin Haematol; 2019 Jun; 32(2):186-191. PubMed ID: 31204000
[TBL] [Abstract][Full Text] [Related]
20. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
